πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

2,263 results for β€œCancer” Clear

  1. MEDROXYPROGESTERONE , Opevesostat, EXEMESTANE , LETROZOLE , MEGESTROL , FLUDROCORTISONE , TAMOXIFEN , FULVESTRANT , HYDROCORTISONE , DEXAMETHASONE

    Merck Sharp and Dohme

    Breast cancer, Ovarian cancer, Endometrial cancer

    phase 3 small molecule active

    1 trial

  2. METHYLPREDNISOLONE , CellCept 500 mg film-coated tablets, PREDNISONE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL , ANAKINRA , RoActemra 20 mg/mL concentrate for solution for infusion, DEXAMETHASONE , Acasunlimab

    Genmab A/S

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  3. MITOMYCIN , JNJ-42756493, GEMCITABINE

    Janssen-Cilag International N.V.

    High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations

    phase 3 small molecule active

    1 trial

  4. MK-1022, CAPECITABINE , PACLITAXEL , TRASTUZUMAB DERUXTECAN , PACLITAXEL ALBUMIN-BOUND, DOXORUBICIN , DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL

    Merck Sharp and Dohme

    Hormone receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  5. MK-2870, CAPECITABINE , CYCLOPHOSPHAMIDE , PACLITAXEL , DEXAMETHASONE , DOXORUBICIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, EPIRUBICIN , CARBOPLATIN

    Merck Sharp and Dohme

    Breast Cancer: triple negative breast cancer (TNBC) and hormone receptor (HR)-low positive/HER2 negative breast cancer

    phase 3 small molecule active

    1 trial

  6. MK-2870, PACLITAXEL ALBUMIN-BOUND, -, PACLITAXEL , -, -, DOXORUBICIN , PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS

    Merck Sharp and Dohme

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  7. MK-2870, PARACETAMOL , TOPOTECAN , -, TISOTUMAB VEDOTIN, IRINOTECAN , PEMETREXED , -, -, GEMCITABINE , MK-2870, VINORELBINE

    Merck Sharp and Dohme

    Recurrent or metastatic cervical cancer that has progressed on or after treatment with platinum-doublet systemic chemotherapy and anti-PD-L1/anti-PD-1 therapy.

    phase 3 small molecule active

    1 trial

  8. MK-4280A, TRIFLURIDINE, COMBINATIONS, REGORAFENIB

    Merck Sharp and Dohme

    Colorectal Cancer

    phase 3 small molecule active

    1 trial

  9. MRTX1719, CARBOPLATIN, CISPLATIN, PEMETREXED, MRTX1719 Matching Placebo, PACLITAXEL ALBUMIN-BOUND, PEMBROLIZUMAB, PACLITAXEL

    Bristol-Myers Squibb / Pfizer EEIG

    metastatic non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  10. MYCOPHENOLATE MOFETIL, ETOPOSIDE, DURVALUMAB, INFLIXIMAB, SILTUXIMAB, Tarlatamab, CARBOPLATIN, Tarlatamab

    Amgen Technology (Ireland) UC

    Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.

    phase 3 small molecule active

    1 trial

  11. Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study

    Institut fΓΌr biomedizinische Analytik NMR-Imaging GmbH

    Maintenance treatment in metastatic non-squamous lung cancer

    phase 3 other active

    1 trial

  12. Medpulser Electroporation with Bleomycin

    INOVIO PHARMACEUTICALS, INC.

    Head Neck Cancer

    phase 3 other terminated

    1 trial

  13. MiLES

    Turn Therapeutics

    Cancer

    phase 3 other active

    1 trial

  14. Micofenolato de mofetil Generis 250 mg CΓ‘psulas, Inflectra 100 mg powder for concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Gemcitabine 100 mg/ml Concentrate for Solution for Infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Oxaliplatine Accord 5 mg/ml concentraat voor oplossing voor infusie

    AstraZeneca AB

    Advanced Biliary Tract Cancers

    phase 3 small molecule active

    1 trial

  15. Mycofit, 250 mg, kapsuΕ‚ki twarde, volrustomig, Saline, Remsima 100 mg powder for concentrate for solution for infusion

    AstraZeneca AB

    Locally advanced cervical cancer

    phase 3 small molecule active

    1 trial

  16. Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, Lynparza 100 mg film-coated tablets, Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Imfinzi 50 mg/ml, Lynparza 100 mg, Lynparza 150 mg, Myfenax 250 mg hard capsules, Flixabi 100 mg p

    AstraZeneca AB

    Endometrial Cancer

    phase 3 small molecule active

    1 trial

  17. Myocet

    Teva Pharma GmbH

    Early Primary Breast Cancer

    phase 3 small molecule completed

    1 trial

  18. NDV-01 (sustained-release gemcitabine-docetaxel)

    RELMADA THERAPEUTICS, INC.

    Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)

    phase 3 small molecule terminated

    1 trial

  19. NDV-01 (sustained-release gemcitabine-docetaxel)

    RELMADA THERAPEUTICS, INC.

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 3 small molecule active

    2 trials

  20. NIVOLUMAB, Bemarituzumab, OXALIPLATIN, FOLINIC ACID, Placebo for AMG 552, CAPECITABINE , FLUOROURACIL

    Amgen Technology (Ireland) UC

    Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression

    phase 3 small molecule active

    1 trial

  21. NIVOLUMAB, GEMCITABINE, TEPMETKO 225 mg film-coated tablets, PACLITAXEL, DOCETAXEL, ATEZOLIZUMAB, BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, PEMETREXED

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  22. NKTR-102

    Nektar Therapeutics UK Limited

    Locally Recurrent Breast Cancer

    phase 3 small molecule completed

    1 trial

  23. NUBEQA 300 mg film-coated tablets, Placebo to BAY1841788 film-coated tablet 300 mg

    Cancer Prevention Pharma (Ireland) Limited

    Localised Very High-Risk Cancer of the Prostate

    phase 3 small molecule active

    1 trial

  24. Nadroparin, long term

    China SXT Pharmaceuticals

    Lung Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources